With $30M and Stanford immunotherapy pioneer, biotech eyes one of the toughest brain diseases

The startup believes it not only has a drug that could fix the process behind ALS and frontotemporal dementia but also a biomarker that could speed development.
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.